FRANKLIN LAKES, N.J.,
Nov. 16, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, issued the following statement
regarding today's announcement by Merit Medical Systems, Inc. that
it has signed a definitive agreement to acquire BD's soft tissue
core needle biopsy product line and C. R. Bard's (NYSE: BCR)
Aspira® product line of tunneled home drainage catheters
and accessories, contingent on the completion of the BD acquisition
of Bard:
"Today's announcement of our intent to divest two product lines
is another step forward in the regulatory review process of BD's
planned acquisition of Bard," said Vincent
A. Forlenza, chairman and CEO of BD. "We continue to expect
that the BD and Bard transaction will close in the fourth calendar
quarter of 2017, subject to customary closing conditions and
additional regulatory approvals, including the U.S. Federal Trade
Commission and other regulatory bodies."
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower health care delivery
costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit
bd.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the federal securities laws, including Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements are
based on the current expectations of BD management and are not
predictions of actual performance. These statements are subject to
a number of risks and uncertainties regarding BD and Bard's
respective businesses and the proposed acquisition, and actual
results may differ materially. These risks and uncertainties
include, but are not limited to, the risk that BD and Bard may not
be able to obtain the required regulatory approvals within
management's expected timeframe or at all, as well as factors
discussed in BD's filings with the Securities and Exchange
Commission. The forward-looking statements in this document speak
only as of the date of this document. BD undertakes no obligation
to update any forward-looking statements to reflect events or
circumstances after the date hereof, except as required by
applicable laws or regulations.
Contacts:
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
View original
content:http://www.prnewswire.com/news-releases/bd-statement-on-merit-medical-agreement-to-purchase-bd-bard-product-lines-300557556.html
SOURCE BD (Becton, Dickinson and Company)